Campling, J.
Jones, D.
Chalmers, J. D.
Jiang, Q.
Vyse, A.
Madhava, H.
Ellsbury, G.
Slack, M.
Funding for this research was provided by:
Pfizer UK
Article History
Received: 30 April 2019
Accepted: 12 September 2019
First Online: 11 October 2019
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: Prof. James Chalmers has received research grant support from AstraZeneca, Pfizer, GlaxoSmithKline, Boehringer-Ingelheim and Bayer Healthcare and has participated in advisory boards or lectures for Griffols, AstraZeneca, Pfizer, Napp, Boehringer-Ingelheim and Bayer Healthcare. He has also received remuneration from Pfizer for services as a member of the Steering Committee for this study. Prof. Mary Slack has received personal fees from GSK, Pfizer, AstraZeneca and Sanofi Pasteur as a speaker at international meetings and as a member of advisory boards (outside the scope of the submitted work). She has also worked as a contractor for Pfizer and received remuneration from Pfizer for services as a member of the Steering Committee for this study. James Campling, Dylan Jones, Qin Jiang, Andrew Vyse, Gillian Ellsbury and Harish Madhava are full-time employees and shareholders of Pfizer; no other conflicts of interest to declare.